Latest Breaking News On - Methylmalonic acidemia - Page 7 : comparemela.com

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia - Data presented at ACMG meeting evaluate disease progression in non-transplanted patients and children receiving liver transplantation News provided by Share this article Share this article LEXINGTON, Mass., May 3, 2021 /PRNewswire/  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia (MMA) caused by a deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MMUT). The study results were recently highlighted in a poster presentation at the American College of Medical Genetic and Genomics (ACMG) Annual Clinical Genetics Meeting.

Daniel gruskinBill berryBerry company public relationsGilmartin groupAmerican college of medical geneticLogicbio therapeutics incLogicbio therapeuticsAmerican collegeMedical geneticAnnual clinical geneticsMethylmalonic acidemiaBio therapeuticsர சி து பெர்ரிபெர்ரி நிறுவனம் பொது உறவுகள்கில்மார்டின் குழுஅமெரிக்கன் கல்லூரி